Drugs / VV913
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07507838 | Apr → Dec 2026 expected | — | Vigonvita Life Sciences | Recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT07565792 | May → Dec 2026 expected | — | Vigonvita Life Sciences | Recruiting | No outcome recorded |
| Phase 1 | NCT07372703 | Jan → Sep 2026 overdue | — | Vigonvita Life Sciences | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VV913 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07565792 ↗ |
| Route | Oral | “6 participants will receive VV913 1mg orally” NCT07372703 ↗ |